What is HC Wainwright’s Forecast for TSE:FRX Q3 Earnings?

Fennec Pharmaceuticals Inc. (TSE:FRX) – Analysts at HC Wainwright lowered their Q3 2026 earnings estimates for Fennec Pharmaceuticals in a research report issued to clients and investors on Friday, May 22nd. HC Wainwright analyst R. Selvaraju now expects that the biopharmaceutical company will earn $0.14 per share for the quarter, down from their previous forecast of $0.17. The consensus estimate for Fennec Pharmaceuticals’ current full-year earnings is $0.60 per share. HC Wainwright also issued estimates for Fennec Pharmaceuticals’ Q4 2026 earnings at $0.17 EPS, FY2026 earnings at $0.37 EPS, Q1 2027 earnings at $0.19 EPS, Q2 2027 earnings at $0.28 EPS, Q3 2027 earnings at $0.34 EPS, Q4 2027 earnings at $0.41 EPS and FY2027 earnings at $1.23 EPS.

Separately, B. Riley Financial upgraded shares of Fennec Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, February 11th. One investment analyst has rated the stock with a Strong Buy rating, According to data from MarketBeat.com, Fennec Pharmaceuticals currently has an average rating of “Strong Buy”.

Fennec Pharmaceuticals Price Performance

FRX stock opened at C$13.69 on Monday. Fennec Pharmaceuticals has a 52-week low of C$7.59 and a 52-week high of C$14.24. The company has a 50-day moving average of C$9.80 and a two-hundred day moving average of C$10.49. The stock has a market capitalization of C$475.55 million, a price-to-earnings ratio of -47.21 and a beta of 3.22.

Insider Transactions at Fennec Pharmaceuticals

In other Fennec Pharmaceuticals news, Director Chris Anigeron Rallis sold 8,346 shares of the company’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of C$9.67, for a total transaction of C$80,705.82. Following the completion of the sale, the director directly owned 61,314 shares in the company, valued at C$592,906.38. This represents a 11.98% decrease in their ownership of the stock. 16.20% of the stock is owned by company insiders.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc is a specialty pharmaceutical company committed to the fight against ototoxicity in cancer patients who receive cisplatin-based chemotherapy. Fennec is focused on the commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in cancer patients. PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom ( U.K. ) approval in October 2023 under the brand name PEDMARQSI®. In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, with rights to commercialize PEDMARQSI® in Europe, U.K., Australia and New Zealand.